All genomic sequencing revealed mutations in KRAS and p53 inthe genomic DNA of EVs derived from pancreatic cancer, suggesting that EV DNA sequencingcan be used to determine treatment plans and predict therapy resistance[141]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.